Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy

DOI:
10.2215/CJN.16631020

Document Version
Final published version

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Published in:
Clinical journal of the American Society of Nephrology : CJASN

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6B0] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy

Amit Sethi,1 Jing Miao,2 Maria Alice V. Willrich,3 Jody L. Frinack,3 Daniel C. Cattran,4 and Fernando C. Fervenza

1University of Minnesota, Minneapolis, Minnesota
2Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota
3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
4Toronto General Research Institute, Division of Nephrology, University of Toronto, Toronto, Canada

Correspondence: Dr. Fernando C. Fervenza, Division of Nephrology and Hypertension, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905. Email: fervenza.fernando@mayo.edu

Primary membranous nephropathy, the most common causes of nephrotic syndrome in White adults, results from glomerular damage secondary to deposition of IgG and complement components in the glomerular basement membrane. In 70%–80% of patients with membranous nephropathy, the disease is due to antibodies against the phospholipase A2 receptor (PLA2R) present on the podocyte cell surface (1). These antibodies are predominantly of the IgG4 subclass. However, the complement activating properties of IgG4 through the classic pathway of complement at the surface level are considered minimal. Yet, large amounts of complement proteins are present in the glomeruli of patients with membranous nephropathy, suggesting that the complement proteins in membranous nephropathy may be derived from activation of the alternative pathway or the lectin pathway of complement (1).

In support of a role of alternative pathway of complement in membranous nephropathy, Seikrit et al. (2) reported three patients with PLA2R-positive membranous nephropathy who developed anticomplement factor H (anti-CFH) antibodies. In the index case, circulating anti-PLA2R antibodies became undetectable, but high levels of anti-CFH developed and were associated with progressive loss of kidney function. Because CFH is critical in regulating the alternative pathway of complement, the authors suggested that anti-CFH antibodies may play a role in the activation of the alternative pathway of complement in at least a subset of patients with membranous nephropathy and that patients with unexplained progression of membranous nephropathy should be screened for anti-CFH antibodies. However, Valoti et al. (3) screened 81 patients with membranous nephropathy for anti-CFH antibodies and failed to find a single case of positive anti-CFH antibodies. To further evaluate the prevalence of anti-CFH antibodies in membranous nephropathy and whether anti-CFH antibodies correlated with outcomes, we evaluated sera from 128 patients with membranous nephropathy enrolled in the Membranous Nephropathy Trial of Rituximab (MENTOR) trial (4) for the presence of anti-CFH antibodies using the commercially available ELISA assay (Generic Assays) that was validated in our laboratory according to Food and Drug Administration standards. Results above the cutoff of 18.8 U/ml were considered positive (Figure 1A).

Anti-PLA2R was also tested using ELISA assay (Euroimmun), and >20 U/ml was defined as positive.

Four (3%) patients were positive for anti-CFH antibodies at baseline, a percentage almost identical to that in the study by Seikrit et al. Three of our four patients also had PLA2R-positive membranous nephropathy (patients 1, 2, and 4), and one had PLA2R-negative membranous nephropathy (patient 3). Three patients were treated with rituximab and achieved complete (patients 1 and 3) or partial (patient 2) remission of proteinuria. In two of these patients, anti-CFH became negative (patients 1 and 2). However, in one of these three patients, anti-CFH antibodies remained positive (patient 3), although the patient achieved complete remission. On the other hand, one patient treated with cyclosporin tested negative for anti-CFH antibodies at all subsequent follow-up time points but failed to achieve remission of proteinuria (patient 4) (Figure 1, B and C). This suggests that there is no consistent relationship between anti-CFH antibody status and treatment outcome, in all likelihood because these antibodies are not of pathophysiologic significance, especially considering their low titer. This would be supported by a careful review of the index case by Seikrit et al. (2) where, despite initial positivity of both autoantibodies, proteinuria and impaired kidney function, the subsequent course showing further deterioration in kidney function could be attributed to a number of possible reasons, including persistent high anti-PLA2R antibody levels (note that PLA2R levels during remission in kidney function could be attributed to a number of possible reasons, including persistent high anti-PLA2R antibody levels (note that PLA2R levels during 18-month interval between October 2010 and April 2012 were not provided). The subsequent partial recovery of both kidney function and reduction in proteinuria was associated with disappearance of the anti-PLA2R antibodies, while anti-CFH antibodies remained positive.

If anti-CFH antibodies were putatively involved in the pathobiology, kidney function should have continued to deteriorate and proteinuria would have remained at the very high levels. In our patients, proteinuria response correlated with anti-PLA2R antibody levels in the two patients who responded to treatment (patients 1 and 2), and the one with a very high titer was resistant to therapy (patient 4). This is consistent with previous studies showing a strong correlation between a reduction in anti-PLA2R antibody levels and response to immunosuppression (5).
The strength of our study is that this is the largest cohort of membranous nephropathy tested for anti-CFH antibodies using routine laboratory testing. Time course evaluation of anti-CFH antibodies was performed, and detailed treatment and outcomes data were available for all patients.

Our study confirms that anti-CFH antibodies are present in a small subset of patients with membranous nephropathy, but the prevalence is low. The anti-CFH antibodies do not appear to consistently correlate with anti-PLA2R antibody levels, degree of proteinuria, or treatment outcome, although the sample size of patients with positive anti-CFH antibodies is limited. On the basis of our data, evaluating every patient with membranous nephropathy for anti-CFH antibody in routine laboratory testing is not warranted at this time.
employment with the Mayo Clinic. M.A.V. Willrich reports employment with the Mayo Clinic; consultancy agreements with Sebia Inc.; receiving research funding from The Binding Site, Sebia Inc., and Siemens Healthineers; and serving as a scientific advisor or member of the Clinical Chemistry and Laboratory Medicine (by De Gruyter) editorial board, as vice chair of the Diagnostic Immunology and Flow Cytometry Committee of the College of American Pathologists, and as chair of the Clinical Diagnostic Immunology Division of the American Association for Clinical Chemistry. All remaining authors have nothing to disclose.

Funding
The study was funded by the Mayo Nephrology Collaborative Group – Mayo Clinic Foundation and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Acknowledgments
The Membranous Nephropathy Trial of Rituximab (MENTOR) was supported by the Fulk Family Foundation and Genentech Inc.

References


A.S. and J.M. contributed equally to this work.

Published online ahead of print. Publication date available at www.cjasn.org.